Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539925 | 0.83 | TLR7 (0.53) | TLR7 | |
| SCHEMBL4520921 | 0.81 | ADORA2B (0.37) | ADORA2BGRM5DRD2DRD4GRM2 | |
| SCHEMBL4530686 | 0.81 | ADORA2B (0.38) | ADORA2BPDPK1AKT1MEN1KMT2A | |
| SCHEMBL4535692 | 0.81 | SMN1; SMN2 (0.39) | PDPK1AKT1MEN1KMT2AABCG2 | |
| SCHEMBL4539942 | 0.78 | MAPT (0.42) | MEN1KMT2ATLR7 | |
| SCHEMBL4519659 | 0.76 | ALDH1A1 (0.38) | PDPK1AKT1MEN1KMT2ALMNA | |
| SCHEMBL4531255 | 0.76 | MEN1 (0.43) | ADORA2BMEN1KMT2ALMNAEGFR | |
| SCHEMBL4533404 | 0.74 | TLR7 (0.52) | MEN1KMT2ATLR7 | |
| SCHEMBL4519524 | 0.73 | TLR7 (0.51) | TLR7 | |
| SCHEMBL1895853 | 0.69 | TLR7 (0.53) | MEN1KMT2ATLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802853-B2 | Arylalkenyl and arylalkynyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20090030030-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-29 | — | — | US | disclosed |
| EP-1701955-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066170-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030030-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | ADORA2B 2284/4885GRM5 3795/4885PDPK1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.